Abstract: Disclosed are methods for the enhancement of nucleic acid delivery systems. The methods may employ treatment with a compound and/or an RNAi molecule in combination with a nucleic acid to improve nucleic acid uptake into a cell. In particular, the disclosed methods may be useful for improved gene therapy techniques.

Abstract: Methods and compositions relating to sterilized fecal microbiota and compositions derived from the same. A method of sterilizing a fecal composition to obtain a sterilized fecal composition is provided. Methods of further purifying the sterilized composition and optionally freezing or freeze-drying the compositions is also provided. Methods of using the compositions for treatment in beverages, foods, and in supplements are also provided.

Abstract: The invention relates, in part, to compounds, compositions, and methods to assess molecular characteristics papillary microcarcinoma (PMC) of the thyroid and indicators of indolent compared to aggressive PMC of the thyroid. In addition, the invention relates, in part, to methods of assessing characteristics of microRNAs associated with PMC of the thyroid.

Abstract: The present invention relates to a biomarker of epilepsy, a composition for diagnosing epilepsy, an epilepsy-induced animal, and a composition for preventing or treating epilepsy, and specifically, relates to a composition for diagnosing epilepsy comprising a BRAF mutant protein and a nucleic acid molecule, and an agent capable of detecting the protein or nucleic acid molecule, an epilepsy-induced animal transformed with the BRAF mutant nucleic acid molecule, and a composition for prevention or treatment of epilepsy comprising a BRAF mutant protein activity inhibitor.

Abstract: Provided herein are Compositions and Methods of Generating Novel amiRNA's. Provided herein are methods for producing or generating one or more amiRNAs; also provided are constructs and compositions useful in the methods. The methods and constructs provided in this disclosure are highly efficient methods for production of a new generation of amiRNAs.

Abstract: Disclosed herein are the genetic constructs for a Homology-Independent Universal Genome Editing (HiUGE) system and methods of using said HiUGE system for genome editing. The invention relates to compositions comprising gRNA polynucleotides, insert polynucleotides, and a CRISPR-based nuclease or polynucleotide encoding a CRISPR-based nuclease.

Abstract: The present invention relates to a process for producing an ethanol-free vanilla extract, and an ethanol-free vanilla extract obtainable by the process according to the invention. In particular, the present invention relates to an ethanol-free vanilla extract comprising at most 100 mg/kg ethanol, the use of this ethanol-free vanilla extract and products comprising the ethanol-free vanilla extract. The focus of the present invention is in particular to provide an ethanol-free vanilla extract which contains only traces of ethanol naturally contained in fermented vanilla beans and is produced without the use of ethanol.

Abstract: The present invention relates to the use of a quantity of one or more water-soluble calcium salts and a quantity of glass particles for preparing platelet releasate from a sample of a platelet-rich blood composition obtained from a subject, wherein said quantity of glass particles is from 0.010 g to 0.60 g per ml of said sample and said quantity of the one or more water-soluble calcium salts is from 1.0 ?mol to 12.0 ?mol per ml of said sample. Systems and methods for preparing a platelet releasate are also disclosed, as well as the platelet releasate obtained therefrom and the use thereof in in vitro and in vivo applications.

Abstract: The present invention relates to a butter comprising a vegetable oil and said hydrogenated vegetable oil.

Abstract: The invention includes compositions and methods for the treating or preventing endometriosis in a subject in need thereof. In one aspect, the invention relates to compositions and methods for modulating let-7 microRNA.

Abstract: The present disclosure relates to the technical field of traditional Chinese herbal composition, and in particular to a traditional Chinese herbal composition for the treatment of bacterial vaginosis and a preparation method thereof. The traditional Chinese herbal composition for the treatment of bacterial vaginosis provided by the present disclosure is prepared from the following components in parts by weight: 40-50 parts of Zingiberis Rhizoma Recens, 35-45 parts of Schisandrae Chinensis Fructus, 30-40 parts of Cinnamomi Cortex, 30-40 parts of Artemisiae Argyi Folium, 25-35 parts of Codonopsis Radix, 25-35 parts of a compound traditional Chinese herbal fermentation broth, 20-30 parts of Pulsatillae Radix, 20-25 parts of Lonicerae Japonicae Flos, 15-20 parts of Taraxaci Herba, 15-20 parts of Akebiae Caulis, 10-15 parts of Polygoni Cuspidati Rhizoma et Radix, and 5-10 parts of Atractylodis Macrocephalae Rhizoma.

Abstract: Provided herein are compositions comprising aptamers that specifically bind monocytes and/or macrophage and methods for their use. These aptamer compositions can be used in methods for isolating and/or enriching monocytes and/or macrophages or depleting cell populations of monocytes and/or macrophages. Further provided are methods of using the aptamers or cell populations generated using them in the methods disclosed herein for therapies and/or drug delivery.

Abstract: The invention relates to a RNA interference triggers for inhibiting the expression of an AAT gene through the mechanism of RNA interference. The invention also relates to a pharmaceutical composition comprising the AAT RNAi trigger together with an excipient capable of improving delivery of the RNAi trigger to a liver cell in vivo. Delivery of the AAT RNAi trigger to liver cells in vivo provides for inhibition of AAT gene expression and treatment of alpha 1-antitrypsin deficiency and associated diseases.

Abstract: One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. Other aspects of the invention relate to pharmaceutical compositions comprising these dsRNA molecules suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA molecules, e.g., for the treatment of various disease conditions.

Abstract: The present invention provides a composition for delivering a polynucleotide into cells via a polyplex. The polyplex comprises the polynucleotide and a polymer. The composition comprises the polyplex, a collagen-mimetic peptide (CMP) and collagen fragments. The CMP is bound to the polyplex and the collagen fragments. Also provided are the uses of the composition in methods of delivering a polynucleotide into cells as well as methods of improving wound healing in a subject, enhancing cell proliferation in a subject, enhancing production of extracellular matrix by cells in a subject and/or enhancing cell migration by cells in a subject.

Abstract: The present disclosure relates to utilizing the N6-methyllysine for reducing fat percentage in an organ or tissue or for treating obesity, obesity-related diseases or cancers. More specifically, the present invention relates to the method using N?-Methyl-L-lysine or N?-Methyl-L-lysine producing bacteria or N?-Methyl-L-lysine/l-lysine mixture or N?-Methyl-L-lysine/probiotics mixture to treat obesity, obesity-related diseases or cancers.

Abstract: Interfering nucleic acids and methods of their use in treat prostate cancers, such as aggressive prostate cancers. The nucleic acids may be, for example, short interfering RNA (siRNA), short hairpin RNA (shRNA), antisense RNA, antisense DNA, Chimeric Antisense DNA/RNA, and microRNA (miRNA) oligonucleotides. The oligonucleotide has a seed sequence that is complementary to a sequence of either a gene or an mRNA encoding an androgen receptor (AR) coregulator or a fragment thereof having AR coregulator activity. The nucleic acid compound may have a non-natural modification in the oligonucleotide, and/or an organic moiety conjugated to the oligonucleotide. The oligonucleotide has inhibitory activity against the expression or biological activity of the AR coregulator.

Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2?-O-methyl nucleotides and 2?-fluoro nucleotides. Further disclosed herein are siNA molecules comprising (a) a phosphorylation blocker, conjugated moiety, or 5?-stabilized end cap; and (b) a short interfering nucleic acid (siNA).

Abstract: Methods for ex vivo expansion of very small embryonic like stem cells in the absence of feeder cells are provided. In some embodiments the methods include providing a plurality of VSELs; and growing the VSELs in a culture medium that includes a histone deacetylase inhibitor, luteinizing hormone, follicle-stimulating hormone, and optionally transforming growth factor beta in an amount that is sufficient to overcome quiescence of the VSELs. Also provided are feeder cell-free cell cultures, ex vivo expanded VSELs, pharmaceutical compositions that include the disclosed ex vivo expanded VSELs, methods for overcoming quiescence in VSELs, methods for re-establishing imprinting in VSELs, method for treating injuries to tissues in subjects, methods for repopulating cell types in subjects, methods for bone marrow transplantation, methods for treating radiation exposure in subjects, and methods that relate to regenerative medicine.

Abstract: The present invention aims to provide an antisense oligonucleic acid with reduced hepatotoxicity. The antisense oligonucleic acid according to the present invention is characterized in that it has a base length of not less than 7 nt and not more than 30 nt, wherein nucleic acid residues of not less than 1 nt and not more than 5 nt respectively from the both terminals are 2?,4?-bridged nucleic acids, 2?,4?-non-bridged nucleic acid residue(s) is(are) present between the above-mentioned both terminals, and one or more bases in the nucleic acid residue(s) of the above-mentioned 2?,4?-non-bridged nucleic acid residue(s) is/are modified.